Amgen (AMGN) Tops Q3 EPS by 47c; offers guidance

Amgen (NASDAQ: AMGN) reported Q3 EPS of $5.58, $0.47 better than the analyst estimate of $5.11. Revenue for the quarter came in at $8.5 billion versus the consensus estimate of $8.51 billion.

GUIDANCE:

Amgen sees FY2024 EPS of $19.20-$20.00, versus the consensus of $19.51. Amgen sees FY2024 revenue of $33-33.8 billion, versus the consensus of $33.2 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low
• Parsons wins $665M Army contract for support services